Podcast
MSL Talk: Tom Caravela, Paul Ward
Why is it so hard to get into oncology
Summary
In this episode, Mary Miao shares her journey and experiences in the oncology field, offering insights into the unique challenges and strategies for breaking into this specialized area. Mary discusses the distinctions between oncology and other therapeutic areas, providing valuable advice for aspiring oncology MSLs. She emphasizes the importance of networking within the oncology community, preparing effectively for MSL roles, and making applications stand out. Mary also highlights the significance of documenting work, maintaining a strong CV, and leveraging LinkedIn for networking. The episode concludes with Mary's advice on embracing humility and continuous learning, along with a promotion for the MSL best practices conference.
My guest today is Mary Miao, Oncology Medical Science Liaison with Immunogen. Mary shares insights on why it is so hard to get into oncology.
This episode is sponsored by Momentum Events and the 2nd MSL Best Practices Summit, virtual event on September 14-15. For more info: https://momentumevents.com/msl-bestpractices/
Mary discusses…
👉 Why there is so much interest in oncology
👉 Why it is difficult to get into the oncology space
👉 How oncology is different from other Therapeutic Areas
👉 What someone needs to do to get into an oncology position
👉 How to prepare yourself to make a successful transition once you're in
oncology MSL, oncology medical science liaison, breaking into oncology, oncology career advice, MSL best practices conference
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Paul Ward
Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
Article
iNIZIO
Transforming oncology: Five frontiers driving progress in cancer care
Article
iNIZIO